NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has agreed to cover Myriad Genetics' prostate cancer aggressiveness test Prolaris for patients who are at intermediate risk for the disease.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.